SCYNEXIS INC - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by SCYNEXIS, Inc. on October 29, 2014, regarding an event that occurred on the same date. The company, incorporated in Delaware, is based in Durham, North Carolina.
Key Financial Metrics and Agreement Terms
The filing details a Material Definitive Agreement rather than periodic financial results. Key financial terms of the agreement include:
- Upfront Payment: $1.0 million for the exclusive license of compound SCY-635.
- Option Fee: Potential additional $500,000 if the option for compounds SCY-575 and SCY-116 is exercised.
- Milestone Payment: $4.0 million payable upon the first registration of a product.
- Royalties: Mid-single digit percentage of net sales, varying by compound.
The filing text does not provide clear values for the company's overall revenue, profit, cash flow, margins, debt, or liquidity as this is an event-driven report.
Material Changes and Agreement Scope
On October 29, 2014, SCYNEXIS entered into an Exclusive License Agreement with Waterstone Pharmaceutical (HK Limited). The agreement grants Waterstone:
- An exclusive, worldwide license to develop and commercialize SCY-635 for viral diseases in humans.
- An 18-month option to obtain an exclusive, worldwide license for SCY-575 and SCY-116.
SCYNEXIS agreed to a non-compete clause, prohibiting the development or licensing of cyclophilin inhibitors for viral diseases in Asia (excluding Japan) during the agreement term. The agreement expires upon the last royalty payment, defined as the later of ten years from the last product registration or the expiration of relevant patents.
Outlook, Risks, and Contingencies
Termination Rights: Either party may terminate for breach. SCYNEXIS retains the right to terminate if Waterstone fails to make reasonable progress in development or commercialization, provided Waterstone fails to remedy the deficiency after notice.
Risks: Future revenue is contingent upon Waterstone exercising the option, achieving product registration, and generating net sales. The filing does not provide specific management commentary on broader company outlook or other risks beyond the terms of this agreement.
Key Facts for Investor Verification
- Verify the receipt of the $1.0 million upfront payment and its impact on cash flow.
- Monitor the 18-month window for Waterstone to exercise the option on SCY-575 and SCY-116.
- Track development milestones for SCY-635 to assess the likelihood of the $4.0 million registration fee.
- Confirm the specific "mid-single digit" royalty percentages in the definitive agreement text.
- Assess Waterstone Pharmaceutical's capability and track record in developing and commercializing viral disease treatments.